Renewal-Harmonization of Technical Requirements for Pharmaceuticals for Human Use (U01) Clinical Trials Not Allowed | RFA FD 21 002

Opportunity Information: Apply for RFA FD 21 002

This grant opportunity, titled "Renewal - Harmonization of Technical Requirements for Pharmaceuticals for Human Use (U01) Clinical Trials Not Allowed" (Funding Opportunity Number RFA-FD-21-002), is a discretionary funding announcement from the U.S. Department of Health and Human Services, Food and Drug Administration (FDA). It uses a cooperative agreement mechanism (U01), which generally means the FDA expects to have substantial involvement in the funded activities rather than acting only as a pass-through funder. The program sits within broad activity areas that include consumer protection, health, science and technology, and research and development, and it is listed under CFDA 93.103.

The core purpose of the award is to support the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) in continuing its work to bring together pharmaceutical regulatory authorities and pharmaceutical industry associations from multiple global regions and jurisdictions. The emphasis is on convening stakeholders and coordinating consensus-building efforts so that scientific and technical standards for pharmaceuticals are more aligned across countries. In practical terms, the work centers on the development, refinement, and promotion of harmonized expectations for how medicines are studied, assessed, and registered, with the goal of reducing unnecessary duplication and friction between regulatory systems.

The public health rationale behind the opportunity is that harmonized technical standards can help speed the development and registration of medicines while maintaining strong safeguards for safety, effectiveness, and quality. When regulators across regions adopt common or closely aligned requirements, pharmaceutical developers can generate evidence and prepare regulatory submissions more efficiently, potentially lowering development burdens and accelerating access to important therapies. The program is framed around making the overall process more resource-efficient for both regulators and industry, while still protecting patients and ensuring that products reaching the market meet high standards.

The expected output of this harmonization work is a set of internationally recognized guidelines used in pharmaceutical product registration. These guidelines are intended to be adopted by regulators in regions around the world, influencing how applications are prepared and evaluated and shaping consistent technical expectations across different markets. Because the opportunity explicitly states "Clinical Trials Not Allowed," the funded scope is not meant to support the conduct of clinical studies; instead, it focuses on the coordination, convening, and guideline-development activities that underpin global regulatory alignment.

This is a renewal-oriented opportunity in which the FDA announces its intention to consider and accept a renewal application for an award to ICH, and it anticipates making a single award. The funding level shown includes an award ceiling of $500,000, with one expected award, indicating a targeted, specific investment aimed at sustaining and advancing ICHs harmonization mission rather than supporting a broad competitive field of unrelated projects. Key dates listed include a creation date of July 8, 2020, and an original closing date of October 13, 2020. Eligibility is listed as "Others" with additional clarification referenced in the full announcement, but the description makes clear the intended recipient is ICH for a renewal application.

Overall, the opportunity is best understood as FDA support for an established international forum that develops consensus technical guidelines for pharmaceuticals. The long-term impact FDA is seeking is a more consistent global regulatory landscape that helps ensure high-quality medicines can be developed and registered efficiently, ultimately improving worldwide patient access to safe and effective therapies.

• The Department of Health and Human Services, Food and Drug Administration in the consumer protection, food and nutrition, health, science and technology and other research and development sector is offering a public funding opportunity titled "Renewal-Harmonization of Technical Requirements for Pharmaceuticals for Human Use (U01) Clinical Trials Not Allowed" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.103.
• This funding opportunity was created on Jul 08, 2020.
• Applicants must submit their applications by Oct 13, 2020. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Each selected applicant is eligible to receive up to $500,000.00 in funding.
• The number of recipients for this funding is limited to 1 candidate(s).
• Eligible applicants include: Others (see text field entitled Additional Information on Eligibility for clarification).

Apply for RFA FD 21 002

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: